论文部分内容阅读
ｏｓｅｎｂｅｒｇ创建的白介素２／淋巴因子（ＩＬ２／ＬＡＫ）激活杀伤细胞是以免疫调节为基础的抗癌免疫疗法，这一疗法的临床研究及应用已取得了很大进展〔１，２〕。研究证明ＩＬ２在血浆中的分布时相半衰期很短，只有６～１３ｍｉｎ。血浆中可能存在ＩＬ２的...
The interleukin-2/lymphokine (IL-2/LAK)-activated killer cells created by Osenberg are immunomodulatory-based anti-cancer immunotherapies. The clinical research and application of this therapy have made great progress[1,2] . Studies have shown that the distribution of IL 2 in plasma has a short half-life, only 6 to 13 minutes. There may be IL-2 in the plasma...